Earlier in March 2017, the drug was approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma. However, we believe it is possible if it gets approval for additional indications for which it is being tested, including gastric cancer, ovarian cancer and non-small cell lung cancer. Pfizer is focused on strengthening its oncology business, which currently contributes less than 20% of the company’s valuation, according to our estimates. Pfizer hasn’t seen any significant growth in its oncology segment until recent years with Ibrance. See More at Trefis | View Interactive Institutional Research (Powered by Trefis)Get Trefis TechnologyLike our charts?

Source: Forbes September 27, 2017 18:33 UTC